Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 155.01 0.35% 0.54
ALXN closed up 0.35 percent on Friday, April 9, 2021, on 45 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ALXN trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 28.13%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 30.40%
Multiple of Ten Bearish Other 30.40%
Inside Day Range Contraction 30.40%
Oversold Stochastic Weakness 30.40%
Stochastic Buy Signal Bullish 31.65%
Multiple of Ten Bearish Other 31.65%
Outside Day Range Expansion 31.65%
Lower Bollinger Band Touch Weakness 31.65%
Oversold Stochastic Weakness 31.65%
Older End-of-Day Signals for ALXN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alexion Pharmaceuticals, Inc. Description

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Clinics Healthcare Providers Therapeutic Product Therapeutic Products Genetic Disease Hemoglobin Metabolic Disorders C3 Hemoglobinuria Inflammatory Disorders Myasthenia Myasthenia Gravis Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Hemolytic Uremic Syndrome Humanized Antibody Kidney Transplant Pnh Atypical Hemolytic Uremic Syndrome Blood Disorder Blood Disorders Hospital Buying Groups Renal Transplant

Is ALXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 162.6
52 Week Low 94.82
Average Volume 2,210,598
200-Day Moving Average 130.25
50-Day Moving Average 153.58
20-Day Moving Average 153.19
10-Day Moving Average 153.94
Average True Range 2.13
ADX 14.61
+DI 28.51
-DI 20.07
Chandelier Exit (Long, 3 ATRs ) 149.57
Chandelier Exit (Short, 3 ATRs ) 156.26
Upper Bollinger Band 155.86
Lower Bollinger Band 150.53
Percent B (%b) 0.84
BandWidth 3.48
MACD Line 0.31
MACD Signal Line 0.13
MACD Histogram 0.1827
Fundamentals Value
Market Cap 33.92 Billion
Num Shares 219 Million
EPS 4.31
Price-to-Earnings (P/E) Ratio 35.97
Price-to-Sales 4.69
Price-to-Book 2.45
PEG Ratio 0.78
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 156.47
Resistance 3 (R3) 156.48 156.00 156.23
Resistance 2 (R2) 156.00 155.63 156.00 156.15
Resistance 1 (R1) 155.51 155.40 155.76 155.50 156.07
Pivot Point 155.03 155.03 155.15 155.02 155.03
Support 1 (S1) 154.53 154.66 154.78 154.52 153.95
Support 2 (S2) 154.05 154.43 154.05 153.87
Support 3 (S3) 153.56 154.05 153.79
Support 4 (S4) 153.55